Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England

Kaatje Bollaerts *, Maria Alexandridou, Thomas Verstraeten

Epidemiology and Pharmacovigilance, Koning Leopold III Laan 1, 3001 Leuven, Belgium

ARTICLE INFO

Article info

Article history:
Received 22 October 2018
Received in revised form 11 December 2018
Accepted 14 December 2018
Available online 29 January 2019

Keywords:
Herpes zoster
Shingles
Vaccine
Vaccine failure
Effectiveness

ABSTRACT

Background: The United Kingdom introduced routine vaccination with the live-attenuated zoster vaccine for 70-year-olds in 2013, with the vaccine also offered to 79-year-olds as part of a catch-up campaign. In the subsequent years, the catch-up campaign was extended to also include adults aged 78 years. We investigated 14 pre-identified potential risk factors for potential modified vaccine effectiveness.

Methods: This retrospective cohort study in England included subjects born in 1943–1946 (the routine cohort) and in 1934–1937 (the catch-up cohort). We used the Clinical Practice Research Datalink (CPRD) to identify herpes zoster (HZ) cases and the risk factors: age, gender, ethnicity, socio-economic status, asthma, type 2 diabetes, chronic obstructive pulmonary disease, smoking, body mass index, immunosuppression, history of HZ, co-administration with influenza or pneumococcal vaccine. We derived HZ incidence by risk groups, overall vaccine effectiveness (VE) and modified VE expressed as relative differences in VE from Poisson regression models.

Results: Overall VE was 66.8% [95% CI: 62.2; 71.0]. Two out of the 14 investigated risk factors modified the HZ VE. Notably, lower VE was observed in diabetics and in persons with a history of HZ with relative differences in VE of –22.2%, [95% CI: –39.6; –4.5] and –22.5%, [95% CI: –44.9; –0.1].

Conclusions: Live-attenuated zoster vaccine protection against HZ was lower in type 2 diabetics and in subjects with a history of HZ. Contrary to clinical trial results, age did not affect the observed VE. Further study is required to gain insights into why certain risk groups are less protected. Identifying and understanding the effect modifiers of VE is important for future vaccine development as well as vaccine recommendations.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Herpes zoster (HZ), or shingles, results from reactivation of latent varicella-zoster virus (VZV) that reside in nerve cells following a primary infection manifesting as chickenpox, typically acquired during childhood. HZ is characterized by a unilateral dermatomal rash and pain, which usually lasts between two weeks and one month [1]. The incidence and severity of HZ increases with age, peaking at 75–85 years of age [2]. The most common complication is persistent chronic pain or post-herpetic neuralgia (PHN), lasting months after the rash has healed and significantly impairing quality of life [3]. In the United Kingdom, the estimated incidence among those 50 years and older is 5.23/1000 person-years, with about 20% of patients developing PHN at least one month after HZ diagnosis [2].

Since 2013, the UK has offered the zoster vaccine Zostavax®, a single-dose live-attenuated herpes zoster vaccine, was approved by the European Medicines Agency in 2012 for the prevention of HZ and PHN in adults aged 50 years and older [4]. The vaccine is contraindicated for persons following immunosuppressive therapy or otherwise with a weakened immune system, as well as for pregnant women and those with active tuberculosis [4]. In a clinical trial setting Zostavax® demonstrated a vaccine efficacy against HZ of 51.3% (95% CI: 44.2–57.6%) in adults aged 60–69 years, and 37.6% in those aged 70 years or older [5]. Following its introduction into the UK on 1st September 2013, the vaccine has been routinely offered to adults at 70 years of age, and to adults aged 79 years as part of a catch-up campaign [6]. In the subsequent years, the catch-up campaign was extended to also include adults aged 78 years. Vaccination coverage one year after vaccine introduction was

https://doi.org/10.1016/j.jvacx.2019.100007
2590-1362/© 2019 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
61.8% for the routine cohort and 59.6% in the catch-up cohort [6]. Several observational studies of the vaccine effectiveness (VE) of Zostavax® have been conducted in the United States, where it has been licensed for adults aged ≥60 years since 2006. These studies reported overall VE estimates from 33% to 55% against HZ [7–10]. In line with their earlier vaccination impact estimations [11], a recent study in the UK with a median follow-up time of 1.42 person-years post-vaccination found a slightly higher VE against HZ (64%; 95% CI: 60, 68%) [12], likely explained by the shorter follow-up period after vaccination in this study compared to the other studies.

As VE might be influenced by many factors, including host factors, logistical issues and epidemiological factors [13], we performed this observational cohort study to add to the existing knowledge by investigating host factors for Zostavax® vaccine failure against HZ in elderly over 70 years of age in England. Based on our review of the literature, we investigated the following potential risk factors: age, gender, ethnicity, socio-economic status, asthma, type 2 diabetes, chronic obstructive pulmonary disease (COPD), smoking, body mass index (BMI), immunocompromised conditions or immunosuppressive or immuno-modulating therapy, a history of HZ prior to vaccination and co-administration with influenza and with pneumococcal vaccine.

2. Methods

The study protocol was approved by the Independent Scientific Advisory Committee for MHRA database research [ISAC protocol. 17_081].

2.1. Data sources

Data were extracted from the Clinical Practice Research Data-link General Practice Database (CPRD-GOLD) linked with the Hospital Episode Statistics Admitted Patient Care data (HES APC) and the Small area level deprivation data (IMD – 2015). The CPRD-GOLD is a primary care database of anonymized patient electronic medical records (EMRs) and is representative of the UK population with regards to age, sex and ethnicity [14]. The CPRD-GOLD currently covers quality data on 6.9% of the UK population [14] and has been validated for use in pharmacoepidemiologic research [15]. Patient information is mostly entered using Read codes, being standard clinical terminology used in UK general practice. Prescriptions are entered using Gmepscript codes based on the NHS dictionary of medicines and devices.

The HES APC includes data on all admissions and visits to National Health Service (NHS) hospitals in England. It is estimated that 98–99% of hospital activity in England is funded by the NHS [16]. The information in HES APC is recorded using the International Classification of Diseases-10 codes (ICD-10). Approximately 75% of the CPRD-GOLD practices in England are linked to the HES APC.

The IMD-2015 database contains a range of socio-economic measures at small area level in England, including the composite measure ‘Index of Multiple Deprivation’ (IMD).

2.2. Study cohort and follow-up

We retrospectively analysed data from subjects born in 1943–46 (routine cohorts) and in 1934–37 (catch-up cohorts). Zoster events were identified starting from the 1st January of the year the majority of the birth cohort (i.e those with their birthday prior to September 1st) became eligible for vaccination. For all routine cohorts, this is the year of the 70th birthday. For the 1934–35 and the 1936–37 catch-up cohorts, this is year of the 79th and the 78th birthdays, respectively. Subjects were included if they had at least 12 months of pre-study quality data to ensure ascertainment of new cases of HZ, had quality data for at least 12 months after inclusion, to ensure ascertainment of HZ complications (not reported here), and were eligible for linkage with HES APC and with IMD to ascertain the risk factors. Subjects were excluded if their date of vaccination was missing or they had indeterminate vaccination information, if they had received zoster vaccine prior to the year of vaccine introduction (i.e. January 1st, 2013), had a missing date of HZ, a PHN diagnosis without HZ diagnosis, or had the HZ diagnosis at the same date as the vaccination date. Subjects were followed continuously from study inclusion until first occurrence of HZ (as such, excluding recurrent events), death, patient transfer out of practice date, GP last data collection date or the end of the study (i.e. 31st December 2016).

2.3. Exposure- and outcome ascertainment

Vaccination status with Zostavax® was ascertained based on Read codes, positive immunization status in the CPRD immunization dataset or products codes (code list in Supplementary Appendix A). Subjects were considered vaccinated at the date of vaccination. HZ was defined as a first HZ event during the study period with the date of onset being the date of earliest evidence of HZ. Community-based HZ and PHN (exclusion criteria) cases were identified by Read codes and hospitalized cases by ICD-10 codes (code list in Supplementary Appendix A).

2.4. Factors affecting vaccine effectiveness

Lopalco and DeStefano have proposed that four types of host factors can affect VE, namely age, presence of conditions or co-morbidities that may either affect immune response or influence individual disease susceptibility, previous exposure to the antigen and interference due to co-administered vaccines or other drugs [13]. Conditions or co-morbidities that may influence susceptibility to HZ were identified based on a review of prior studies. The investigated risk factors for modified VE are summarized in Table 1.

Table 1.

2.5. Statistical analyses

Risk factors for modified VE were investigated using Poisson regression models. We first built the main effects model by simplifying the full model containing zoster vaccination status and all risk factors (Table 1) as main effects. Model simplification was done using the Chi-square likelihood ratio test at 5% significance level, dropping the least significant terms first until only significant terms remained, resulting in the simplified main effects model. Routine vs catch-up cohort (proxy for age), sex and exposure status were not considered for model exclusion. Then, to estimate differential VE in each risk group while accounting for differences in HZ baseline risk, interaction terms between exposure status and the risk factors were added one at a time to the simplified main effects model. In case the risk factor of interest was not included in the simplified main effects model, it was added to allow proper interpretation of the interaction term related to that risk factor. The HZ incidences (per 1000 person year) by HZ baseline risk factors and the overall VE were derived from the simplified main effects model. The relative increases/decreases in VE (in %) by risk group were derived from the simplified model with added interaction terms and the delta method was used to obtain 95% confidence intervals (CIs).
| Risk factor | Description | Source |
|-------------|-------------|--------|
| **(i) Age** | Age group (routine vs catch-up cohort) | [17,18] |
| **(ii) Factors that may either affect immune response or influence individual disease susceptibility** | | |
| **Demographics** | | |
| Gender | | [17,18] |
| Ethnicity (Caucasian vs non-Caucasian) | Code list in Appendix A | [17,18] |
| Socio-economic status (Index of Multiple deprivation (IMD); IMD < 5th quintile vs 5th quintile) | | [17,18] |
| **Chronic conditions** | | |
| Asthma | | [17,19] |
| Type 2 diabetes | | [20] |
| Chronic obstructive pulmonary disease (COPD) | Code list in Appendix A | [17,21] |
| **Life style factors** | | |
| Smoking (smoker, ex-smoker, non-smoker) | Status was ascertained using the most recent information up to five years prior to study inclusion. Code list in Appendix A | [22] |
| Body Mass Index (BMI) (underweight, normal, overweight/obese) | | |
| **Immunosuppression** | | |
| Immunocompromised conditions | Treated as time-varying. Subjects considered immunocompromised from their first record of their immunocompromised condition onwards if they have any record of acute/chronic leukaemia and lymphomas, HIV/AIDS, cellular immune deficiencies or haematological malignancies. Patients are considered immunocompromised for 2 years after each record of haematopoietic stem cell transplant. Code list and details in Appendix A | [23] |
| -Acute and chronic leukaemias and lymphomas | | |
| -HIV/AIDS | | |
| -Cellular immune deficiencies | | |
| -Haematological malignancies | | |
| -Allogenic or autologous haematopoietic stem cell transplants | | |
| Immunosuppressive or immunomodulating therapies | Treated as time-varying. Patients are considered immunosuppressed when an immunosuppressive or immunomodulating therapy record is found until 3 months after each record. Code list and details in Appendix A | [23] |
| -Immunosuppressive chemotherapy or radiotherapy for malignant disease or non-malignant disorders | | |
| -Immunosuppressive therapy for a solid organ transplant | | |
| -Biological therapy (e.g. anti-TNF therapy such as alemtuzumab, ofatumumab and rituximab) | | |
| - Therapy with short term high-dose corticosteroids or long term lower dose corticosteroids or non-biological oral immune modulating drugs | | |
| **(iii) Previous exposure to the antigen** | History of herpes zoster prior to study inclusion | [11] |
| **(iv) Interference due to co-administered vaccines or other drugs** | Co-administration with influenza vaccine | Co-administration at the same day. Code list in Appendix A. | [23] |
| Co-administration with pneumococcal vaccine | | [23] |

Fig. 1. Attrition diagram.
3. Results

In the linked dataset we identified quality-records of 111,810 subjects belonging to the routine or catch-up cohorts, of which 434 (0.39%) were excluded – initially 211 (0.19%) for indeterminate vaccination status or having been vaccinated before January 1st 2013, and a further 223 (0.20%) due to missing HZ data, diagnosis of PHN rather than HZ, or having HZ and vaccination on the same date (Fig. 1). This yielded a total of 111,376 subjects for analysis. The median follow-up time was 2.0 person-years, with an median follow-up time of 1.3 person-years post-vaccination.

The routine and catch-up cohorts combined accounted for a total of 143,122 and 112,597 person years, respectively (Supplementary Appendix B). Overall, the population was 88% Caucasian, 53% female, 45% non-smoking and 55% overweight or obese (i.e. having a BMI > 25 to < 30 or > 30, respectively). Approximately 14%, 20% and 7.9% of the population had asthma, type 2 diabetes and COPD, respectively (Fig. 2).

For each risk factor, we evaluated percentage vaccination coverage two years after the respective age cohort became eligible for vaccination as vaccine uptake increases rapidly the first year after vaccination eligibility and plateaus afterwards [11]. Vaccination coverage was slightly higher in the catch-up cohorts (53.7%) compared with the routine cohorts (52.7%) (Fig. 3). Non-Caucasians (41.5%), smokers (41.0%), subjects who were underweight (47.5%) and subjects with a low socio-economic status (47.6%) were vaccinated less. Vaccination was also less frequent in the immunocompromised (41.0%) or while subjects were immunosuppressed (0.88%) (Fig. 3). The zoster vaccine was often given concomitantly with influenza (35.8%), but rarely with the pneumococcal vaccine (1.3%).

![Diagram](image)

Fig. 2. Proportions (%), by risk factor. *Immunocompromised conditions were evaluated at the end of subject’s follow-up. **Subjects were considered immunosuppressed when having at least one period of immunosuppression during their follow-up time.
The HZ incidence (per 1000 person years) in the general unvaccinated population was 9.34 (95% CI: 8.78, 9.90), assuming no other HZ risk factors were present. The main effects model showed a higher HZ incidence among females compared to males, Caucasians compared to non-Caucasians and among asthma patients, patients with a history of HZ, patients with immunocompromising conditions or who are immunosuppressed compared to the overall population (Table 2). The estimated overall VE against HZ was 66.8% (95% CI: 62.2, 71.0).

Type 2 diabetes and history of HZ differentially affected the VE with a relative difference in VE of −22.2% for diabetics compared to non-diabetics (95% CI: −39.6, −4.5) and a relative difference of −22.5% for subjects with compared to subjects without a history of HZ (95% CI: −44.9, −0.1) (Table 3).

4. Discussion

In this retrospective database study, we found that in adults ≥70 years of age the live-attenuated HZ vaccine had an overall VE against herpes zoster of 66.8% (95% CI: 62.2, 71.0). However, we found that this VE was not equal in all population groups. More specifically, we found that diabetics and persons who previously experienced HZ are less well protected by the vaccine compared with persons who do not have such risk factors. These two population groups combined represent 28.5% of the entire population for whom the vaccine is recommended. The relative difference in VE was −22.2% (95% CI: −39.6, −4.5) for diabetics compared to non-diabetics and −22.5% (95% CI: −44.9, −0.1) for subjects with compared to subjects without a history of HZ.
The effect of diabetes on vaccination has been studied for some vaccines such as Hepatitis B and influenza vaccines. Several studies have shown a decreased seroconversion rate following hepatitis B vaccination in diabetics [24,25]. Relatively few studies have assessed the effect of diabetes on VE in the real-world setting. One recent study found a significantly increased effectiveness of the conjugated pneumococcal vaccine against vaccine-type community-acquired pneumonia when administered to elderly diabetics in a large randomized trial in the Netherlands [26]. However, in studies of other vaccinations among diabetics, mostly influenza vaccines, no clear impact was seen on immunogenicity [27], or on VE [28,29]. Surprisingly we could not replicate the expected increased risk of HZ among the diabetics in our study [20]. Further analyses may be needed to analyse whether disease severity or use of medication may be associated with the decreased VE observed in our study.

The lower VE we found in subjects with a history of HZ was also found in the recent study on the first three years of the UK programme; VE was 47% (95% CI; 31, 58%) in those with prior zoster versus 64% (95% CI; 60, 68%) in those without previous zoster [12]. The authors postulated that this finding might be explained by a differential uptake among those with a relatively recent zoster episode, whereby persons with a recent zoster (temporarily protected against a new episode) would be less likely to be vaccinated compared with subjects with a less recent zoster (less protected as a result of waning immunity) [12]. We could not confirm this hypothesis as we found that the vaccination uptake was comparable in those with a recent (≤5 years) and less recent (>5 years) HZ episode prior to vaccination eligibility (32.4% and 30.7%).

Our estimated overall VE against HZ of 66.8% (95% CI; 62.2, 71.0) is higher than the estimates found in a clinical trial (56%; 95% CI: 40, 67) [5], but is comparable with values found in other observational studies [8]. This is probably explained by differences in length of follow-up after vaccination and differences in captured cases (mild cases are more likely to be captured by the active surveillance in clinical trials compared with healthcare database studies) and the finding that the vaccine offers higher protection against more severe zoster [5,8]. Contrary to the clinical trial results, our results did not show differences in overall VE by age. Absence of an age effect was also observed in previous observational studies on zoster VE [8,12,30].

The VE against zoster was also not affected by co-administration with the influenza vaccine. In the UK, General Practitioners were encouraged to administer zoster concomitantly with inactivated influenza vaccine [23]. The zoster vaccine can be co-administered with the 23-valent pneumococcal polysaccharide vaccine although a single study had shown an inferior VZV antibody response in those receiving both vaccines concomitantly [31]. We found that 35.8% of the zoster vaccines was given on the same day as the influenza vaccine but only 1.3% was given on the same day as the pneumococcal vaccine.

Although at increased HZ risk (Table 2), patients with immunocompromised conditions or those on immunosuppressive or immuno-modulating therapy are contra-indicated for zoster vaccination, or at least the vaccine should be used cautiously [23]. We found that the recommendation not to vaccinate subjects on immunosuppressive therapy was well followed by medical practitioners, with the low number of vaccinations (0.9%) in these groups of patients possibly explained by misclassification. We did not find any evidence that immunosuppressed subjects were less protected by the vaccine. Of the 2.5% of the population that was classified as immunocompromised, 41.0% was still vaccinated. Although as expected, the HZ baseline incidence was higher in the immunocompromised (Table 2) compared with the immunocompetent free of HZ risk factors, the high vaccination coverage in immunocompromised subjects is unexpected. This finding might be explained by coding inconsistencies [6]. Such a high vaccination coverage in immunocompromised subjects was also recently found in another study [32].

While we also found the zoster VE to be unaffected by age, gender, ethnicity, socio-economic status, asthma, COPD, BMI or smoking, the absence of any significant differences, especially when the risk factor is less frequent, should be treated cautiously as it might be explained by a lack of statistical power. Additional limitations of our study that apply to both the significant and non-significant findings include the potential misclassification of exposure, outcome and risk factors. As the zoster vaccine is administered at General Practices, the exposure misclassification is expected to be limited. The same holds for outcome misclassification with the misclassification of the medically attended HZ being unlikely as HZ is a largely clinical diagnosis. Misclassification seems more likely for some of the risk factors. A substantial amount of missing information was observed for ethnicity (8.3%), BMI (21.1%) and smoking (12.0%). The index of multiple deprivation is a variable at small area level, not at the individual level, possibly introducing ecological bias. Despite our attempts to minimize misclassification of chronic (asthma, COPD, type 2 diabetes) and immunocompromised conditions by linking to hospital data, misclassification can still arise as a result of incomplete medical histories or coding inconsistencies.

In spite these limitations, we believe that healthcare databases are a good source for the study of risk factors for modified VE due to their large size. In our database study, we found that a large proportion of the population, specifically those with diabetes and prior history of HZ, benefit less from the live-attenuated HZ vaccine compared with the rest of the population. Age, gender, ethnicity, socio-economic status, asthma, COPD, smoking, BMI, immunosuppression and co-administration with influenza and with pneumococcal vaccine were not found to modify the VE. Our study illustrates the importance of assessing VE by subpopulations. Identifying and understanding the effect modifiers of VE is important for future vaccine development as well as vaccine recommendations. Our findings might be particularly relevant in the light of the likely licensure of the new zoster adjuvanted recombinant vaccine Shingrix<sup>®</sup> in the UK. Unlike the live-attenuated zoster vaccine Zostavax<sup>®</sup>, the recombinant zoster vaccine is also indicated for use among immunocompromised patients. Given in a 2-dose series, the new vaccine showed an efficacy at preventing zoster of at least 90% in clinical trials with efficacy above 85% for up to four years after vaccination [33,34]. The real-world effectiveness of the new

| Table 2 | Herpes zoster incidence in unvaccinated populations (per 1000 person-years). |
|---------|--------------------------------------------------------------------------------|
|         | Herpes zoster incidence ([/1000 person-years] [95% CI])                       |
| **General population** |                                                                                     |
| Overall | 9.34 [8.78; 9.90]                                                              |
| Routine cohort | 9.45 [8.72; 10.18]                                                           |
| Catch-up cohort | 9.20 [8.55; 9.85]                                                             |
| Female  | 10.55 [9.80; 11.3]                                                             |
| Male    | 8.14 [7.49; 8.79]                                                              |
| Caucasian | 9.53 [8.95; 10.10]                                                           |
| Non-Caucasian | 5.79 [4.15; 7.43]                                                             |
| Non-smoker | 9.66 [8.94; 10.39]                                                            |
| Ex-smoker | 9.36 [8.54; 10.17]                                                             |
| Smoker  | 8.01 [6.83; 9.26]                                                              |
| **Patient populations** |                                                                                     |
| Asthma  | 11.20 [9.94; 12.45]                                                            |
| Immunocompromised | 15.48 [12.17; 18.79]                                                          |
| Immunosuppressed | 14.23 [10.92; 17.55]                                                          |
| History of herpes zoster | 10.78 [9.39; 12.17]                                                           |
Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326:740–50.

Table 3
Risk factors for modified vaccine effectiveness.

| Risk factor                                      | Number of vaccinated cases | Person-years of vaccinated subjects | Number of unvaccinated cases | Person-years of unvaccinated subjects | Vaccine effectiveness (95% CI) | Relative difference, % (95% CI) |
|--------------------------------------------------|----------------------------|------------------------------------|------------------------------|--------------------------------------|-------------------------------|---------------------------------|
| Age                                              |                            |                                    |                              |                                      |                               |                                 |
| Routine cohort (70 yrs)                           | 130                        | 42,121                             | 952                          | 101,001                              | 0.68 [0.62; 0.74]             | Ref                             |
| Catch-up cohort (78–79 yrs)                       | 123                        | 33,369                             | 773                          | 77,228                               | 0.65 [0.59; 0.72]             | –3.6 [–16.4; 9.1]              |
| Gender                                           |                            |                                    |                              |                                      |                               |                                 |
| Male                                             | 100                        | 36,733                             | 698                          | 83,494                               | 0.68 [0.61; 0.75]             | Ref                             |
| Female                                           | 153                        | 40,757                             | 1027                         | 94,734                               | 0.66 [0.60; 0.72]             | –3.3 [–16.0; 9.5]              |
| Ethnicity                                        |                            |                                    |                              |                                      |                               |                                 |
| Caucasian                                        | 234                        | 70,452                             | 1590                         | 155,707                              | 0.67 [0.63; 0.72]             | Ref                             |
| Non-Caucasian                                    | 10                         | 2470                               | 39                           | 6993                                 | 0.27 [–0.23; 0.78]            | –59.3 [–134.0; 15.5]           |
| Index of Multiple Deprivation                    |                            |                                    |                              |                                      |                               |                                 |
| < 5th quintile                                   | 229                        | 69,798                             | 1553                         | 157,422                              | 0.67 [0.63; 0.72]             | Ref                             |
| 5th quintile                                     | 24                         | 7674                               | 171                          | 20,744                               | 0.63 [0.47; 0.79]             | –6.0 [–30.3; 18.2]             |
| Asthma                                           |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 209                        | 65,970                             | 1427                         | 153,096                              | 0.67 [0.62; 0.71]             | Ref                             |
| Yes                                              | 44                         | 11,520                             | 298                          | 25,132                               | 0.68 [0.58; 0.78]             | 1.8 [–15.2; 18.8]              |
| Type 2 diabetes                                  |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 183                        | 61,470                             | 1395                         | 143,769                              | 0.70 [0.65; 0.75]             | Ref                             |
| Yes                                              | 70                         | 16,020                             | 330                          | 34,460                               | 0.55 [0.43; 0.66]             | –22.0 [–39.6; –4.5]            |
| Chronic obstructive pulmonary disease (COPD)     |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 232                        | 71,632                             | 1569                         | 161,994                              | 0.67 [0.62; 0.71]             | Ref                             |
| Yes                                              | 21                         | 5858                               | 156                          | 14,234                               | 0.67 [0.52; 0.82]             | 0.8 [–22.6; 24.2]              |
| Smoking                                          |                            |                                    |                              |                                      |                               |                                 |
| Non-smoker                                       | 133                        | 36,757                             | 800                          | 77,434                               | 0.65 [0.59; 0.71]             | Ref                             |
| Ex-smoker                                        | 83                         | 26,604                             | 567                          | 57,061                               | 0.68 [0.61; 0.76]             | 5.0 [–10.2; 20.3]              |
| Smoker                                           | 20                         | 5984                               | 167                          | 20,368                               | 0.60 [0.41; 0.78]             | –8.4 [–38.5; 21.8]             |
| Body mass index (BMI)                            |                            |                                    |                              |                                      |                               |                                 |
| Normal weight (18.5–24.9)                        | 56                         | 17,309                             | 362                          | 37,062                               | 0.67 [0.58; 0.76]             | Ref                             |
| Underweight (<18.5)                              | 4                          | 1973                               | 59                           | 5476                                 | 0.82 [0.63; 1.00]             | 21.7 [–10.9; 54.4]             |
| Overweight (25–29.9) or obese (>30)               | 159                        | 45,083                             | 962                          | 95,361                               | 0.65 [0.59; 0.71]             | –2.8 [–18.8; 13.3]             |
| Immunocompromised                                |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 241                        | 75,992                             | 1649                         | 173,438                              | 0.67 [0.63; 0.72]             | Ref                             |
| Yes                                              | 12                         | 1498                               | 76                           | 4791                                 | 0.49 [0.19; 0.80]             | –26.8 [–72.8; 19.3]            |
| Immunosuppressed                                 |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 245                        | 75,948                             | 1659                         | 173,949                              | 0.67 [0.62; 0.71]             | Ref                             |
| Yes                                              | 8                          | 1542                               | 66                           | 4280                                 | 0.66 [0.41; 0.91]             | –1.1 [–38.9; 36.7]             |
| History of herpes zoster                         |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 208                        | 68,635                             | 1512                         | 158,845                              | 0.69 [0.64; 0.73]             | Ref                             |
| Yes                                              | 45                         | 8855                               | 213                          | 19,384                               | 0.53 [0.38; 0.68]             | –22.5 [–44.9; –0.1]            |
| Co-administration with influenza vaccine         |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 164                        | 48,708                             | 1725                         | 178,229                              | 0.66 [0.60; 0.71]             | Ref                             |
| Yes                                              | 89                         | 28,782                             | –                            | –                                    | 0.68 [0.62; 0.75]             | 4.0 [–8.9; 17.0]               |
| Co-administration with pneumococcal vaccine      |                            |                                    |                              |                                      |                               |                                 |
| No                                               | 251                        | 76,567                             | 1725                         | 178,229                              | 0.67 [0.62; 0.71]             | Ref                             |
| Yes                                              | 2                          | 923                                | –                            | –                                    | 0.77 [0.45; 1.00]             | 15.2 [–33.5; 63.9]             |

*Ref = reference group.

A recombinant vaccine still needs to be demonstrated and it is recommended to also evaluate potential VE effect modifiers of the new vaccine in order to formulate optimal vaccine recommendations.

5. Author’s contributions

KB and TV designed the study. MA did the data pre-processing and presentation of results. KB performed the statistical analyses and wrote the first draft and subsequent revisions. All authors reviewed and approved the final version before submission.

Acknowledgements

The study was performed under a grant from the Flemish Agency for Innovation by Science and Technology (IWT), Belgium (grant number: IWT 150274). The authors would like to thank Marc Baay (P95 Epidemiology and Pharmacovigilance, Leuven, Belgium) for publication management.

Conflict of interest

KB and TV received consulting fees from Merck for unrelated work. MA reports no conflict of interest.

Appendix Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jvacx.2019.100007.

References

[1] Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326:740–50.
